Entrepreneurship, Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… the start-up DETERA Therapeutics is developing a drug candidate for crescentic glomerulonephritis (CGN). This treatment would enable the 10,000 patients in Europe and America to protect their kidney function, as current … reduced. This will generate savings for the public health system," says the director. To raise awareness, DETERA …Published on: